Press Releases

Date Title and Summary Additional Formats
Toggle Summary Quotient Limited Provides an Update on Recent Milestone Achievements for its MosaiQ Multimodality Multiplexing Diagnostic Platform
Initial Serological Disease Screening FDA 510k Submission Received Commencement of EU Extended Immunohematology Field Trial Activities JERSEY, Channel Islands , Jan. 10, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in
View HTML
Toggle Summary Quotient Announces Appointment of New Chief Financial Officer Peter Buhler and Chief Operating Officer Ed Farrell
Chris Lindop to Remain as Executive Vice President Reporting to Franz Walt CEO              JERSEY, Channel Islands , Jan. 07, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced the planned appointment of Peter Buhler as Chief Financial
View HTML
Toggle Summary Quotient Limited Reports Concordance Data from MDS Concept Study
JERSEY, Channel Islands , Dec. 05, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland , today reported positive concordance data for its MosaiQ™ Multiplex Molecular Disease Screening (MDS) Microarray
View HTML
Toggle Summary Quotient Limited to Participate in the Jefferies 2019 London Healthcare Conference
JERSEY, Channel Islands, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Quotient Limited  (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company’s Chief Executive Officer, Franz Walt , the Company’s President of R&D and Manufacturing, Ed Farrell , and the Company’s Chief
View HTML
Toggle Summary Quotient Limited Announces Closing of Underwritten Offering of Ordinary Shares
JERSEY, Channel Islands, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT) (the Company), a commercial-stage diagnostics company, today announced the closing of its previously announced underwritten public offering of 13,800,000 ordinary shares at a price to the public of $7.00 per
View HTML
Toggle Summary Quotient Limited Announces Pricing of Underwritten Offering of Ordinary Shares
JERSEY, Channel Islands , Nov. 06, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT) (the Company), a commercial-stage diagnostics company, today announced the pricing of its previously announced underwritten public offering of 12,000,000 ordinary shares at a price to the public of $7.00 per
View HTML
Toggle Summary Quotient Limited Announces Proposed Underwritten Offering of Ordinary Shares
JERSEY, Channel Islands, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT) (the Company), a commercial-stage diagnostics company, today announced the Company intends to commence an underwritten public offering of its ordinary shares. All of the ordinary shares to be sold in the
View HTML
Toggle Summary Quotient Limited Provides Positive Updates on MosaiQ’s Initial Serological Disease Screening and Expanded Immunohematology Microarrays, on Hypercare Launch and on a Successful Facility Audit and Reports Second Quarter Fiscal 2020 Financial Results
Positive results from the initial Serological Disease Screening microarray US field trial Positive Verification and Validation data for expanded Immunohematology microarray An additional three Hypercare launch sites initiated in 2019 Successful ISO 13485 : 2016 audit of MosaiQ microarray
View HTML
Toggle Summary Quotient Announces Positive Preliminary Results from the Initial Serological Disease Screening US Field Trial
JERSEY, Channel Islands , Oct. 31, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced positive preliminary US field trial data on the Initial Serological Disease Screening (SDS) Microarray. “We are very encouraged by these results.
View HTML
Toggle Summary Quotient Limited to Report Second Quarter 2020 Financial Results and Host Conference Call
JERSEY, Channel Islands , Oct. 21, 2019 (GLOBE NEWSWIRE) -- Quotient Limited  (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal second quarter ended September 30, 2019, will be released before market open on Monday, November 4, 2019.
View HTML